

Mymetics Corp.

Profile

Ticker **MYMX** | Primary Stock Exchange **OTC Bulletin Board**

Overview: This biotechnology research and development company is developing an HIV vaccine as well as malaria, influenza and Respiratory Syncytial Virus (RSV) vaccines.

Incorporated: INCORPORATED in Delaware in November 1996 as ICHOR Corp. to succeed a Pennsylvania corporation organized on July 20, 1994 as PDG Remediation, Inc., a wholly owned subsidiary of PDG Environmental, Inc. Name changed to Mymetics Corp. in July 2001.

Background: Mymetics Corporation operates as an international biotechnology company focused on developing vaccines to combat a range of diseases. The company exploits its knowledge and intellectual property related to mucosal immunology and virosomes to develop vaccines. It uses these approaches for a portfolio of five vaccines, of which three are in clinical trials stages. Mymetics Corporation developed its portfolio using a mixture of in-house resources, outsourcing, and collaborations with major pharmaceutical companies. Its vaccine portfolio addresses HIV, RSV, herpes, influenza, and malaria. The company's key technologies, which can be exploited across a range of other vaccines, focus on mucosal immunology and the use of virosomes as a delivery method/adjuvant. Virosome based vaccines benefit from their immunogenicity, safety profile, and stability. Mucosal immunology focuses on inducing antibody production at the body's mucosal surfaces, through which most path(Continued on the next page of this report)

Stock Data (Capitalization as of: December 31, 2008)

Stock: **Preferred \$0.01 par** | Authorized Shares **5,000,000** | Outstanding Shares **None**

Stock: **Common \$0.01 par** | Authorized Shares **495,000,000** | Outstanding Shares **194,313,630**

Footnote: **1. Excl. 1,000,000 issuable at Dec. 31, 2008.**

Long Term Debt **Euro 8,973,000.**

Stockholders (as of March 26, 2009): **600**

Principal Stockholder: **March 26, 2009, Round Enterprises Ltd. owned or controlled 22.9% of the Common, and Ernst Luebke 5.2%.**

Transfer Agent: **Continental Stock Transfer & Trust Co., New York, NY**

Additional Notes:

Dividends

Common Stock

Exchange	Year	High	Low	
OTC Bulletin Board	2008	0.3600	0.0900	
	¹ 2007	0.2500	0.0240	
	Over The Counter	2006	0.0900	0.0001
		² 2005	0.3100	0.0350
		2004	0.3400	0.0450
		2003	0.2200	0.0400
		2002	3.8500	0.0600
		2001	4.1000	1.8700
2000	3.5000	0.2500		
NASDAQ	1999	5.0000	1.0000	

Footnote:

1 Moved from Over The Counter Oct. 24.

2 Moved from OTC Bulletin Board Dec. 27.

Corporate Information

Address:

14, Rue de la Colombiere
Nyon

Phone: 011-41-22-363-13-10

Fax: 011-41-22-363-13-11

Web Site:

http://www.mymetics.com

Auditors:

PETERSON SULLIVAN, P.P.C.

I.R. Contact:

Anthony Jessop

Employees: 8

Shareholders: 600

Founded: 1994

Domicile: Delaware

Officers:

Jacques-Francois Martin Chairman, President & Chief Executive Officer
Ernst Lubke Secretary, Chief Financial Officer, Chief Accounting Officer & Treasurer
Ronald Kempers Chief Operating Officer
Sylvain Fleury Chief Scientific Officer
Anthony Jessop SR VP & Investor Relations Contact

Directors:

Sylvain Fleury
Ernst Lubke
Jacques-Francois Martin
Christian Jean-Francois Rochet
Thomas Staehelin
Ernest M. Stern

Subsidiaries:

6543 Luxembourg S.A.
Mymetics Management Sarl

Profile

Background: (Continued from Page 1) ogens enter the body. Mymetics Corporation plans to develop its vaccines up to the conclusion of Phase II trials, by which point partnerships with large pharmaceuticals will be entered into. The company also focuses on applying its virosomal approach and mucosal immunity approach to a range of vaccines through a combination of selective acquisitions, in-house development, partnerships, and out-licensing. It was formerly known as Hippocampe S.A. and changed its name to Mymetics Corporation on July 31, 2001. The company was founded in 1990 and is based in Epalinges, Switzerland.

Annual Report

Income Statement as of Dec. 31 (Thou. Euros)	2008	2007	Balance Sheet as of Dec. 31 (Thou. Euros)	2008	2007
Government grants	65		ASSETS		
Gain on extinguishment of debt		774	Current Assets		
Expenses			Cash	509	159
Research and development	2,692	5,981	Short-term investments		60
General and administrative	3,693	3,945	Receivables officer	8	71
Interest	583	138	Receivables other	6	
Amortization	17		Prepaid expenses	75	17
Loss before income tax provision	(6,920)	(9,290)	Total current assets	598	307
Income tax provision	(18)	(4)	Property and equipment, net	76	10
Net loss	(6,938)	(9,294)	Total assets	674	317
Basic and diluted loss per share	(0.04)	(0.06)	LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)		
			Current Liabilities		
			Accounts payable	991	2,307
			Taxes and social costs payable	25	4
			Current portion of note payable		2,000
			Other		52
			Total current liabilities	1,016	4,363
			Note Payable, less current portion	8,973	150
			Common stock, U.S. \$.01 par value	1,742	1,694
			Common stock issuable	7	3
			Additional paid-in capital	20,155	18,401
			Deficit accumulated during the development stage	(31,904)	(24,966)
			Accumulated other comprehensive income	685	672
			Total Shareholders' Equity	(9,315)	(4,196)
			Total liabilities	674	317